Ads
related to: olaparib prostate cancer treatment brachytherapy reviews- Side Effects
Learn More About Potential Side
Effects And Safety Information.
- What Is LYNPARZA?
Learn More About How LYNPARZA
Works And If It's Right For You.
- View FAQs
Find Answers To Frequently
Asked Questions.
- Starting LYNPARZA
Learn More About Eligibility For
LYNPARZA Here At The Official Site.
- Clinical Study Data
Access Clinical Study Data For
LYNPARZA At The Official Site.
- Discover MyLYNPARZA
A Support Program Developed To
Provide Patient Education.
- Side Effects
Search results
Results From The WOW.Com Content Network
Brachytherapy is a type of radiotherapy, or radiation treatment, offered to certain cancer patients. There are two types of brachytherapy – high dose-rate (HDR) and low dose-rate (LDR). LDR brachytherapy is the one most commonly used to treat prostate cancer. It may be referred to as 'seed implantation' or it may be called 'pinhole surgery'. [1]
If the cancer has spread beyond the prostate, treatment options change significantly, so most doctors who treat prostate cancer use a variety of nomograms to predict the probability of spread. Treatment by watchful waiting/active surveillance, HIFU, external-beam radiation therapy, brachytherapy, cryosurgery, and surgery are, in general ...
Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor , inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair .
Body sites in which brachytherapy can be used to treat cancer. Brachytherapy is commonly used to treat cancers of the cervix, prostate, breast, and skin. [1]Brachytherapy can also be used in the treatment of tumours of the brain, eye, head and neck region (lip, floor of mouth, tongue, nasopharynx and oropharynx), [10] respiratory tract (trachea and bronchi), digestive tract (oesophagus, gall ...
Pamiparib (BGB-290) For ovarian cancer, 1st patient enrolled May 2018. [30] It is a PARP1 and PARP2 inhibitor. [31] [32] Started Phase II: Olaparib (developed by AstraZeneca) for breast, ovarian and colorectal cancer. [33] [34] Olaparib TOPARP-A trial for use in advanced prostate cancer (published c. April 21, 2015). [35]
Iodine-125 (125 I) is a radioisotope of iodine which has uses in biological assays, nuclear medicine imaging and in radiation therapy as brachytherapy to treat a number of conditions, including prostate cancer, uveal melanomas, and brain tumors. It is the second longest-lived radioisotope of iodine, after iodine-129.
Ads
related to: olaparib prostate cancer treatment brachytherapy reviews